Before Ozempic, Wegovy, Mounjaro and Zepbound, there was Lotte Bjerre Knudsen.
In the 1990s, the young scientist at the Danish drug company Novo Nordisk was trying to unlock the key to a new technology for treating Type 2 diabetes. To her bosses, Lotte’s project, which focused on a hormone called GLP-1, looked like a distraction.
But as Lotte fought to save her diabetes project from the chopping block, she couldn’t have imagined how much of an impact her breakthrough would have. Her work would pave the way for a hit drug called Ozempic. And it would unleash a new class of blockbuster drugs, pitting two companies in a race to become the world’s first trillion-dollar pharmaceutical company by market cap.
Listen to Part 1 of “Trillion Dollar Shot” now.
Learn more about your ad choices. Visit megaphone.fm/adchoices
Why Buying Paramount Global Won't Be Easy
Ukraine's $30 Billion Problem
Argentina’s New President Takes a Chainsaw to the Country’s Government
A Deadly Drone Attack and Iran’s ‘Axis of Resistance’
A Russian Billionaire, an Art Dealer and an Epic Feud
How China's BYD Overtook Tesla
The Company Taking on Apple’s Watch Technology
The Computer Glitch That Caused Nearly 1,000 Convictions
Smuggling Migrants Toward the U.S. Is a Booming Business
How the Stanley Cup Became the Internet's Favorite Water Bottle
What Happens to Privacy in the Age of AI?
Food Fight: PepsiCo vs. Carrefour
Bitcoin's Long Journey to the Stock Market
Artificial: Episode 4, Behind Sam Altman’s Firing
The 2024 College Financial Aid Mess
Will Florida’s Plan to Get Cheap Drugs From Canada Work?
‘We Were Attacked’: Militants Upend Global Shipping
A Hole in a Plane and a Headache for Boeing
A Messy Start to the 2024 Presidential Election
Artificial: Episode 3, ChatGPT
Create your
podcast in
minutes
It is Free
WSJ What’s News
WSJ Your Money Briefing
WSJ Opinion: Potomac Watch
The Daily
Today, Explained